InflaRx (IFRX) Receivables (2024 - 2025)
InflaRx (IFRX) posted Receivables of $3.7 million for Q2 2025, up 94.2% sequentially from $1.9 million in Q4 2024, and up 14519.47% YoY from N/an in Q2 2024.
InflaRx (IFRX) Receivables (2024 - 2025) Analysis & Trends
InflaRx has reported Receivables for 2 years, with the latest figure at $3.7 million in Q2 2025.
- Quarterly Receivables rose 14519.47% year-over-year to $3.7 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $3.7 million (up 14519.47% YoY) and the FY2024 annual result came in at $1.9 million, changed N/A from the prior year.
- Receivables grew to $3.7 million in Q2 2025 per IFRX's latest filing, from $1.9 million in the prior quarter.
- Over five years, Receivables peaked at $3.7 million in Q2 2025 and troughed at $25551.3 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 3.74 Mn |
| Dec 31, 2024 | 1.92 Mn |
| Sep 30, 2024 | 96,172.18 |
| Jun 30, 2024 | 25,551.31 |
| Mar 31, 2024 | 38,285.56 |